Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

The company's focus on mast cell-mediated diseases positions it in a potentially lucrative market. CSU alone affects over three million patients in the United States, with only one FDA-approved ...

Blueprint Medicines' Ayvakit shows strong revenue growth, projected to reach over $2 billion in peak sales. Read my analysis ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell-mediated ...

"Driven by scalable innovation and operational excellence, we aspire to fundamentally shift the way many allergic and inflammatory diseases are treated by targeting the mast cell. We have built a ...

"Driven by scalable innovation and operational excellence, we aspire to fundamentally shift the way many allergic and inflammatory diseases are treated by targeting the mast cell. We have built a high ...

Jasper Therapeutics, Inc. announced promising preliminary results from its BEACON Phase 1b/2a study of briquilimab, an experimental therapy targeting mast cell-driven diseases like chronic ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profileMean change in UAS7 ...